Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | COMT | P21964 | 1/20 | 0.43 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.38 |
| ▸ | WDR77 | Q9BQA1 | 3/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19601807 | 0.84 | PIK3CD (0.53) | PIK3CDNPC1RAB9AL3MBTL1COMT | |
| SCHEMBL24664423 | 0.83 | PIK3CD (0.47) | PIK3CDNPC1RAB9AL3MBTL1COMT | |
| SCHEMBL4390570 | 0.81 | PIK3CD (0.49) | PIK3CDP2RX7PRMT5WDR77 | |
| SCHEMBL16260596 | 0.80 | PIK3CD (1.00) | PIK3CDNPC1RAB9AL3MBTL1COMT | |
| SCHEMBL2619229 | 0.80 | PIK3CD (0.55) | PIK3CDNPC1RAB9AL3MBTL1P2RX7 | |
| SCHEMBL2624402 | 0.79 | PRMT5 (0.59) | NPC1RAB9AL3MBTL1P2RX7POLB | |
| SCHEMBL3419405 | 0.78 | PIK3CD (0.65) | PIK3CDNPC1RAB9AL3MBTL1COMT | |
| SCHEMBL21959946 | 0.78 | PIK3CD (0.65) | PIK3CDNPC1RAB9AL3MBTL1COMT | |
| SCHEMBL22387991 | 0.78 | PIK3CD (0.53) | PIK3CDNPC1RAB9AL3MBTL1P2RX7 | |
| SCHEMBL22012732 | 0.78 | PIK3CD (0.56) | PIK3CDL3MBTL1P2RX7POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KYRAS THERAPEUTICS, INC. | 2017-06-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158702-A1 | MULTIVALENT RAS BINDING COMPOUNDS | KRAS, HRAS, NRAS | PIK3CD 94/4885NPC1 1999/4885RAB9A 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.